DOCSLIB.ORG

Tranexamic Acid in the Management of the Post Adeno-Tonsillectomy Phase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tranexamic Acid in the Management of the Post Adeno-Tonsillectomy Phase Central Annals of Otolaryngology and Rhinology Research Article *Corresponding author Barbara Pittore, Otorhinolaryngology Department, C.T.O, Hospital, Via Cattaneo, 09016 Iglesias, Italy, Tranexamic Acid in the Tel: 39-338-9658-541; Fax: 39-0781-392-2675; E Submitted: 12 August 2015 Management of the Post Adeno- Accepted: 28 August 2015 Published: 31 August 2015 Tonsillectomy Phase Copyright © 2015 Pittore et al. Barbara Pittore1*, Carlo Loris Pelagatti2, Lisa Fraser3, Mauro Cau2, Francesco Deiana2, and Giovanni Sotgiu4 OPEN ACCESS 1 Department of Otorhinolaryngology, C.T.O Hospital, Italy Keywords 2 Department of Otorhinolaryngology, S. Francesco Hospital, Italy • Tonsillectomy 3 Department of Otorhinolaryngology, University Hospital Southampton NHS Foundation • Tranexamic Acid Trust, UK • Morbidity 4 Department of Biomedical Sciences, University of Sassari-Research, Medical Education • Bleeding and Professional Development, Ital Abstract Objective: To evaluate if oral Tranexamic Acid can decrease the proportion of individuals with secondary bleeding in the post-operative adeno-tonsillectomy phase. Study design: Observational, retrospective epidemiological study. Setting: San Francesco Hospital, Nuoro, Italy Patients and methods: Over 20 months 236 children underwent elective adeno-tonsillectomy for chronic tonsillitis and/or otitis media and/or adenotonsillar hypertrophy. Two groups of patients were identified: the first one included 149 patients who took oral Tranexamic Acid (20 mg/Kg daily) for 10 days in the post- operative period, whereas the second one was characterized by 87 patients who did not take Tranexamic Acid. Results: Only 6/236 (2.54%) cases of secondary bleeding were reported; 3/149 (2.01%) belonged to the group taking Tranexamic Acid, whereas 3/87 (3.44%; p-value: 0.5) belonged to the group not exposed to Tranexamic Acid. They were admitted and followed-up for 48 hours; no surgical interventions were performed. Conclusion: Oral Tranexamic Acid did not significantly decrease the proportion of post-adenotonsillectomy bleeding episodes in our cohort. New prospective, randomized, controlled trials are needed to test the effectiveness of that drug in the management of post-adenotonsillectomy hemorrhages episodes. ABBREVIATIONS vascular [4], liver [5], and large orthopedic procedures [6]. SD: Standard Deviation; COM: Chronic Otitis Media; TA: It is estimated that hemorrhages occur in 2-5% [7,8] of Tranexamic Acid the patients following a tonsillectomy, representing the most common and serious complication [9]. While the majority of INTRODUCTION those events are self-limiting, a minority needs to be surgically Tranexamic acid (TA) is a drug used for treating treated [8]. Although extremely rare, sudden severe hemorrhage and preventing bleeding [1]. TA is a synthetic derivative of the may occur and can result in death [10-12]. Post tonsillectomy mortality ranges from 1 per 10.000 individuals [10] to 1 per inhibits the activation of plasminogen to plasmin, a molecule 28.000 [12], with approximately 16% caused by hemorrhages [9, amino acid lysine [2]. It is an antifibrinolytic that competitively 10,12]. sites of both plasminogen and plasmin [2]. Several methods has been used to prevent and reduce the responsible for the degradation of fibrin, by binding to specific The latter molecule is a protein that forms the framework of frequency and the amount of bleeding during and after adeno- blood clots [2]. TA is frequently used in surgical interventions tonsillectomy procedures (e.g., diathermy [13], noose tie [14], characterized by a high risk of blood loss such as in cardiac [3], ultrasonic armonic scalpel [15] and drugs such as TA [16- Cite this article: (2015) Tranexamic Acid in the Management of the Post Adeno-Tonsillectomy Phase. Ann Otolaryngol Rhinol 2(9): 1060. Pittore et al. (2015) Email: Central 20]). The role of TA in the management of hemorrhages is still tympanometry, baseline bloods, electrocardiography and controversial, as discussed by Chan CC et al in a recent systematic anesthesiological assessment. review and meta-analysis [21]. Exclusion criteria for surgical intervention were: previous Aim of this study was to retrospectively compare a group of history of bleeding or spontaneous hematoma, altered pediatric patients who post-operatively took TA with a second coagulation tests, evidence of hematopoietic, cardiovascular, group of children who did not take TA, in order to evaluate a hepatic, renal, neurologic, psychiatric or auto-immune diseases. proportional difference in terms of post-operative bleeding. All 236 patients underwent tonsillectomy by bipolar MATERIALS AND METHODS diathermy technique (using 20-25 Watt) connected to an irrigation system (0.45% saline solution) to decrease the Between January 2012 and September 2013, 236 pediatric diathermy injury in the tonsillar bed. Of the 236 adenoidectomies, patients underwent elective adeno-tonsillectomy for chronic 55 were performed endoscopically (0° degree - 2.7-4 mm rigid tonsillitis and/or otitis media and/or adenotonsillar hypertrophy at the Otorhinolaryngology Department of the San Francesco and a Vision elect HD monitor [Stryker]) using adenotome, and Hospital, Nuoro, Italy. 181scope were [Karl performed Storz] with traditionally a 1188 Hight by Definition mouth using camera adenotome, [Stryker] curette and Juracz forceps. In both cases the hemostasis was included 149 patients who took orally TA (dosage: 10 mg/Kg controlled with an angled bipolar (20-25 Watt). twiceThe daily) patients for 10were days classified in the post-operative into two groups; period, the firstwhereas one Analysis the second group of 87 patients was not treated with TA. Oral antibiotics were prescribed to all individuals consecutively Descriptive analysis of the demographic, epidemiological, selected for this observational study (amoxicillin+ clavulanic acid; and clinical variables was carried out (tables 4). Variables were in case of allergy to penicillin clarithromycin was administered) collected using an ad-hoc electronic-form. Fisher exact test was performed to statistically compare differences between those they were treated with paracetamol for analgesia. treated with TA VS. those non treated with TA. STATA statistical for the first 10 days following the surgical procedure; in addition software (Stata Corp, Stata Statistical Software Release 9, College Pre-operative evaluation included an otolaryngologist Station, TX, USA, 2005) was used to carry out descriptive and examination consisting of anterior and posterior rhinoscopy with a inferential analyses. flexible nasendoscope to assess the grade of adenoid hypertrophy, Table 1: Demographic, epidemiological and clinical characteristics of 236 Sardinian children. Variables Age, mean (SD), years 5.1 (2.1) Male, n (%) 138 (58.5) Adenoid/tonsil hypertrophy, n (%) 165 (69.9) Surgical intervention: endoscopic adeno-tonsillectomy, n (%) 55 (23.3) Allergy to penicillin, n (%) 2 (66.7) Post-surgical intervention antibiotic therapy, n (%) 87 (36.9) Primary bleeding, n (%) 3 (1.3) Secondary bleeding, n (%) 6 (2.5) Occurrence of the secondary bleeding, mean (SD), days 10.7 (2.7) Duration of the surgical intervention, mean (SD), minutes 40.6 (14.1) Abbreviations: SD: Standard Deviation Table 2: VariablesDemographic, epidemiological and clinical characteristics of 236 Sardinian children,Female stratified by gender.Male p-value Age, mean (SD), years 5.3 (2.0) 5.1 (2.2) 0.54 Adenoid/tonsil hypertrophy, n (%) 70 (71.4) 95 (68.8) 0.67 Allergy to penicillin, n (%) 0 (0.0) 2 (100.0) 0.08 Post-surgical intervention antibiotic therapy, n (%) 61 (62.2) 88 (63.8) 0.81 Primary bleeding, n (%) 1 (1.0) 2 (1.5) 0.08 Secondary bleeding, n (%) 1 (1.0) 5 (3.6) 0.21 Occurrence of the secondary bleeding, mean (SD), days 8 (0.0) 11.2 (2.6) - Duration of the surgical intervention, mean (SD), minutes 40.7 (15.6) 40.6 (13.1) 0.92 Ann Otolaryngol Rhinol 2(9): 1060 (2015) 2/4 Pittore et al. (2015) Email: Central Table 3: Adenoid/tonsil Adenoid/tonsil VariablesDemographic, epidemiological and clinical characteristics of 236 Sardinian children, stratified by diagnosis. p-value hypertrophy hypertrophy + COM Age, mean (SD), years 5.4 (2.2) 4.6 (2.0) 0.005 Male, n (%) 95 (57.6) 43 (60.6) 0.67 Allergy to penicillin, n (%) 1 (100.0) 1 (50.0) 0.39 Post-surgical intervention antibiotic therapy, n (%) 101 (61.2) 48 (67.6) 0.35 Primary bleeding, n (%) 2 (1.2) 1 (1.4) 0.90 Secondary bleeding, n (%) 5 (3.0) 1 (1.4) 0.47 Occurrence of the secondary bleeding, mean (SD), days 10.8 (3.0) 10.0 (0.0) - Duration of the surgical intervention, mean (SD), minutes 37.1 (13.7) 48.6 (11.8) <0.001 Abbreviations: SD: Standard Deviation; COM: Chronic Otitis Media Table 4: VariablesDemographic, epidemiological and clinical characteristics of 236Antibiotics Sardinian +children, TA stratified byAntibiotics post-surgical therapy. p-value Age, mean (SD), years 5.2 (2.2) 5.1 (2.0) 0.87 Male, n (%) 88 (59.1) 50 (57.5) 0.81 Allergy to penicillin, n (%) 0 (0.0) 2 (100.0) 0.08 Adenoid/tonsil hypertrophy, n (%) 101 (67.8) 64 (73.6) 0.35 Primary bleeding, n (%) 3 (2.0) 0 (0.0) 0.18 Secondary bleeding, n (%) 3 (2.0) 3 (3.5) 0.50 Occurrence of the secondary bleeding, mean (SD), days 12.0 (2.7) 9.3 (2.3) 0.26 Duration of the surgical intervention, mean (SD), minutes 38.8 (13.7) 43.7 (14.4) 0.009 Abbreviations: SD: Standard Deviation; TA: Tranexamic Acid RESULTS AND DISCUSSION the risk of post-tonsillectomy bleeding [21]. Castelli G et al [18] Out of 236 adeno-tonsillectomies only 6 cases of secondary reduced the mean blood loss, but it did not significantly decrease bleeding (2.54%) were diagnosed; 3/149 (2.01%) were in the reduction of blood loss during the operation and in the post group treated with TA and 3/87 (3.44%) in the second group not surgicalconducted period a randomized after the studyadministration showing statisticallyof TA. George significant A et al exposed to TA (Tables 1-4). They were admitted and followed- up for 48 hours; however, a new surgical intervention was not needed to manage any bleeding episodes.
Load more

Recommended publications
  • WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2016/133483 Al 25 August 2016 (25.08.2016) P O P C T (51) International Patent Classification: SHENIA, Iaroslav Viktorovych [UA/UA]; Feodosiyskyy A61L 15/44 (2006.01) A61L 26/00 (2006.01) lane, 14-a, kv. 65, Kyiv, 03028 (UA). A61L 15/54 (2006.01) (74) Agent: BRAGARNYK, Oleksandr Mykolayovych; str. (21) International Application Number: Lomonosova, 60/5-43, Kyiv, 03189 (UA). PCT/UA20 16/0000 19 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 February 2016 (15.02.2016) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (30) Priority Data: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, a 2015 01285 16 February 2015 (16.02.2015) UA PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, u 2015 01288 16 February 2015 (16.02.2015) UA SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (72) Inventors; and TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Therapeutic Options to Minimize Allogeneic Blood
    Santos AA, etREVIEW al. - Therapeutic ARTICLE options to minimize allogeneic blood Rev Bras Cir Cardiovasc 2014;29(4):606-21 transfusions and their adverse effects in cardiac surgery: A systematic review Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: A systematic review Opções terapêuticas para minimizar transfusões de sangue alogênico e seus efeitos adversos em cirurgia cardíaca: Revisão sistemática Antônio Alceu dos Santos1, MD; José Pedro da Silva1, MD, PhD; Luciana da Fonseca da Silva1, MD, PhD; Alexandre Gonçalves de Sousa1, MD; Raquel Ferrari Piotto1, MD, PhD; José Francisco Baumgratz1, MD DOI: 10.5935/1678-9741.20140114 RBCCV 44205-1596 Abstract Results: Treating anemia and thrombocytopenia, suspending Introduction: Allogeneic blood is an exhaustible therapeutic anticoagulants and antiplatelet agents, reducing routine phle- resource. New evidence indicates that blood consumption is ex- botomies, utilizing less traumatic surgical techniques with moderate cessive and that donations have decreased, resulting in reduced hypothermia and hypotension, meticulous hemostasis, use of topical blood supplies worldwide. Blood transfusions are associated and systemic hemostatic agents, acute normovolemic hemodilu- with increased morbidity and mortality, as well as higher hos- tion, cell salvage, anemia tolerance (supplementary oxygen and pital costs. This makes it necessary to seek out new treatment normothermia), as well as various other therapeutic options have options. Such options
    [Show full text]
  • Management of Bleeding Associated with Malignant Wounds
    JOURNAL OF PALLIATIVE MEDICINE Volume 15, Number 8, 2012 Case Discussions ª Mary Ann Liebert, Inc. DOI: 10.1089/jpm.2011.0286 in Palliative Medicine Feature Editors: Eva H. Chittenden and Craig D. Blinderman Management of Bleeding Associated with Malignant Wounds Katherine Recka, M.D., Marcos Montagnini, M.D., and Caroline A. Vitale, M.D. Abstract Bleeding malignant wounds in palliative care patients can be anxiety-provoking for patients, their caregivers, and healthcare providers, and can be difficult to manage. We present the case of a 60-year-old man with a bleeding neck wound due to squamous cell carcinoma of the hypopharynx admitted to our inpatient palliative care unit. Management of bleeding included local wound care measures and psychosocial support for the patient and his wife. We review therapeutic approaches to managing bleeding malignant wounds with the aim of providing clinically useful information. Introduction On admission, physical examination revealed a cachectic man with a large ulcerated wound along the angle of his jaw leeding associated with malignant wounds can be from just below his left ear to his tracheostomy. The inferior difficult to manage in all settings, but particularly in aspect of the wound approached the left clavicle. The wound B settings in which goals of care center on comfort and quality of had multiple areas of punctuate hemorrhages and required life. We discuss a challenging case of a patient with a persis- frequent dressing changes to absorb the bleeding. There was no tent bleeding malignant neck wound arising from a stage IV significant odor. His tracheostomy secretions were thick and supraglottic squamous cell carcinoma.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Formulary April
    Standard Formulary MedPerform Medium April, 2021 Copyright © 2020 MedImpact Healthcare Systems, Inc. All rights reserved. This document is confidential and proprietary to MedImpact and contains material MedImpact may consider Trade Secrets. This document is intended for specified use by Business Partners of MedImpact under permission by MedImpact and may not otherwise be used, reproduced, transmitted, published, or disclosed to others without prior written authorization. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document. MedPerform Medium Formulary What is the standard formulary? The MedImpact formulary is a list of covered drugs selected by physician and pharmacist subject matter experts who collaboratively support MedImpact’s Pharmacy and Therapeutics (P&T) Committee. The plan will cover drugs listed in the formulary as long as the drug is indicated for the clinical condition, is prescribed in the appropriate manner, the prescription is filled at a participating network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage. Can the Formulary (drug list) change? Drugs may be added or deleted from the formulary during the year. If a drug is removed from the formulary, [or] adds prior authorization, quantity limits and/or step therapy restrictions on a drug or moves a drug to a higher cost-sharing tier], the plan will notify affected members of the change before the change becomes effective. If the Food and Drug Administration (FDA) deems a drug on the formulary to be unsafe or the drug’s manufacturer removes the drug from the market, the plan will immediately remove the drug from the formulary.
    [Show full text]
  • Guidelines on the Management of Bleeding for Palliative Care Patients with Cancer
    Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the management of bleeding for palliative care patients with cancer November 2008 Authors: Dr Bill Hulme and Dr Sarah Wilcox, on behalf of the Yorkshire Palliative Medicine Clinical Guidelines Group. Overall objective : To provide evidence-based guidance for the management of bleeding in cancer patients within specialist palliative care. Search strategy: Medline, CINAHL and Embase databases were searched with the help of an experienced librarian using MESH terms for cancer, neoplasm, the generic and trade names for individual drugs and haemorrhage or site-specific areas for haemorrhage. Searches were limited to papers published in English relating to human adults up until March 2008. References obtained were hand searched for additional materials relevant to this review. Additional searches were also conducted for NICE and SIGN guidelines, Cochrane databases, Clinical Knowledge Summaries and publications from associated Royal Colleges. The bulletin board of palliativedrugs.com and palliative medicine textbooks were also reviewed for expert advice. Level of evidence: Evidence regarding medications included in this review has been graded according to criteria described by Keeley [2003] on behalf of the SIGN research group (see appendix 4). Review date: September 2013 Competing interests: None declared Disclaimer: These guidelines are the property of the Yorkshire Palliative Medicine Clinical Guidelines Group and are intended for qualified, specialist palliative medicine professionals as an information resource. They should be used in the clinical context of each individual patient’s needs and reference to appropriate prescribing texts / literature should also be made. The Clinical Guidelines Group takes no responsibility for any consequences of any actions taken as a result of using these guidelines.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,050,265 B2 Jamis0n Et Al
    US009050265B2 (12) United States Patent (10) Patent No.: US 9,050,265 B2 Jamis0n et al. (45) Date of Patent: Jun. 9, 2015 (54) VITAMIN CAND VITAMINK, AND (56) References Cited COMPOSITIONS THEREOF FOR TREATMENT OF OSTEOLYSIS OR U.S. PATENT DOCUMENTS PROLONGATION OF PROSTHETIC 6,468.414 B1 10/2002 Mahdavi et al. IMPLANT 6,599.945 B2 7/2003 Docherty et al. 7,091,241 B2 8, 2006 Gilloteaux et al. (75) Inventors: James M. Jamison, Stow, OH (US); 2002fO1464637,094.809 A1B2 10,8, 20062002 phyDocherty et al. Thomas M. Miller, El Cajon, CA (US); 2003/0073738 A1 4/2003 Gilloteaux et al. Deborah R. Neal, Uniontown, OH (US); 2007/0043.11.0 A1 2/2007 Gilloteaux et al. Mark Willam Kovacik, Mogadore, OH 2008/0081041 A1 4/2008 Nemeth (US); Michael John Askew, 39S A1 33.9 Miller SA Strongsville, OH (US); Richard Albert 2011/0028436 A1 2/2011 Greenwa Mostardi, Ravenna, OH (US) 2011 0160301 A1 6, 2011 Tsai et al. FOREIGN PATENT DOCUMENTS (73) Assignee: Summa Health System, Akron, OH (US) CN 101537174 9, 2009 JP 2006131611 A 5, 2006 WO O247493 A2 6, 2002 (*) Notice: Subject to any disclaimer, the term of this WO 2007 147128 A2 12/2007 patent is extended or adjusted under 35 WO 2009 118726 A2 10, 2009 (21) Appl. No.: 13/384,574 Bullough, “Metallosis.” J. Joint Bone Surg. Br., 1994, 76, 687-688. Rae, “The toxicity of metals used in orthopaedic prostheses. An experimental study using cultured human synovial fibroblasts.” J. (22) PCT Filed: Jul.19, 2010 Joint Bone Surg.
    [Show full text]
  • Procedure Description Price HC NEWBORN CHARGE STATISTIC
    Procedure Description Price HC NEWBORN CHARGE STATISTIC 0.00 HC ADMISSION CHARGE 584.43 HC ADM HSCRC RATE CHANGE 584.43 HC ANESTHESIA PER MINUTE 2.05 HC ANS HSCRC RATE CHANGE 2.05 HC ANESTHESIA - PAIN MANAGEMENT 2.05 HC ANESTHESIA - SPINE 2.05 HC ANESTHESIA - CARDIAC SURGERY 2.05 HC ANESTHESIA - CARDIOLOGY 2.05 HC ANESTHESIA - DENTISTRY 2.05 HC ANESTHESIA - ELECTROCONVULSIVE THERAPY (ECT) 2.05 HC ANESTHESIA - EMERGENCY SURGERY 2.05 HC ANESTHESIA - GENERAL SURGERY 2.05 HC ANESTHESIA - MEDICINE 2.05 HC ANESTHESIA - NEUROSURGERY 2.05 HC ANESTHESIA - OPHTHALMOLOGY 2.05 HC ANESTHESIA - ORGAN TRANSPLANT 2.05 HC ANESTHESIA - ORTHOPEDICS 2.05 HC ANESTHESIA - OTOLARYNGOLOGY 2.05 HC ANESTHESIA - PEDIATRIC SURGERY 2.05 HC ANESTHESIA - PLASTIC SURGERY 2.05 HC ANESTHESIA - SURGICAL ONCOLOGY 2.05 HC ANESTHESIA - THORACIC SURGERY 2.05 HC ANESTHESIA - TRAUMA GENERAL 2.05 HC ANESTHESIA - UROLOGY 2.05 HC ANESTHESIA - VASCULAR SURGERY 2.05 HC ANESTHESIA - WOMEN'S HEALTH 2.05 HC ANESTHESIA - GASTROENTEROLOGY 2.05 HC ANESTHESIA - ORAL MAXILLOFACIAL 2.05 HC ANESTHESIA - PEDIATRIC MEDICINE 2.05 HC ANESTHESIA - PODIATRY 2.05 HC ANESTHESIA - ANESTHESIA 2.05 HC ANESTHESIA - PEDIATRIC CATH 2.05 HC ANESTHESIA - PEDIATRIC GASTRO 2.05 HC ANESTHESIA - PEDIATRIC HEM ONC 2.05 HC ANESTHESIA - PULMONARY 2.05 HC HYDRATION IV INFUSION INIT 429.60 HC HYDRATE IV INFUSION ADD-ON 214.80 HC THER/PROPH/DIAG IV INF INIT 429.60 HC THER/PROPH/DIAG IV INF ADDON 214.80 HC TX/PROPH/DG ADDL SEQ IV INF 214.80 HC THER/DIAG CONCURRENT INF 35.80 HC TX/PRO/DX INJ NEW DRUG ADDON 107.40 HC IRRIG
    [Show full text]
  • Topical Delivery of Alpha1-Antichymotrypsin for Wound
    Topical delivery of α1-Antichymotrypsin for wound healing Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München vorgelegt von Roland Schmidt aus Treuchtlingen München 2005 Erklärung Diese Dissertation wurde im Sinne von § 13 Abs. 3 und 4 der Promotionsordnung vom 29. Januar 1998 von Herrn Prof. Dr. G. Winter betreut. Ehrenwörtliche Versicherung Diese Dissertation wurde selbständig, ohne unerlaubte Hilfe erarbeitet. München, 01. Januar 2005 (Roland Schmidt) Dissertation eingereicht am: 10. Januar 2005 1. Berichterstatter: Prof. Dr. G. Winter 2. Berichterstatter: Prof. Dr. W. Frieß Tag der mündlichen Prüfung: 1. Februar 2005 ACKNOWLEDGMENTS Foremost, I wish to express my deepest appreciation to my supervisor, Prof. Dr. Gerhard Winter. I am much obliged to him for his professional guidance and his scientific support. On a personal note, I especially want to thank him for inspiring my interest in protein pharmaceuticals, for teaching me so much, and for creation of an outstanding working climate. I am also grateful to the Switch Biotech AG, Neuried, Germany for financial support. I would like to acknowledge Dr. Uwe Goßlar for rendering every assistance and the always professional and personally warm contact. Moreover, I would like to thank Annette, Björn, and especially Olivia for performing the Bioassays. Thanks are also extended to Prof. Dr. Bracher, Prof. Dr. Frieß, PD Dr. Paintner, Prof. Dr. Schlitzer, and Prof. Dr. Wagner for serving as members of my thesis advisor committee. I very much enjoyed working at the Department for Pharmaceutical Technology and Biopharmaceutics of the Munich Ludwig-Maximilians-University, what was mainly due to the cooperative and most convenient atmosphere.
    [Show full text]
  • WO 2016/069458 Al 6 May 2016 (06.05.2016) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/069458 Al 6 May 2016 (06.05.2016) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/122 (2006.01) A61P 1/18 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/375 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/057336 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 26 October 2015 (26.10.201 5) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/069,156 27 October 2014 (27. 10.2014) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: SUMMA HEALTH SYSTEM [US/US]; 525 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, E.
    [Show full text]